Menu
Recruiting NCT05974150

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

— Observational Breast Cancer Lung Cancer Multiple Myeloma Ovarian Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Web based survey.
Who it may be relevant to
Registry conditions: Breast Cancer, Lung Cancer, Multiple Myeloma, Ovarian Cancer. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia (AML) Using Remote Symptom Monitoring

Overview

The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic patient reported outcome (PRO) surveys are collected from the patients using the Carevive platform for a minimum of 12 weeks. Patients may continue weekly surveys as long as they are receiving treatment.

Interventions

  • Other Web based survey
    online weekly survey

Primary outcome measures

  • Create Data Set [Time frame: 1 year]

Eligibility criteria

Inclusion criteria

  • All participants must be 18 years of age or older.
  • Subjects may be any stage and anywhere in the treatment continuum.
  • Subject participants must have a diagnosis of a breast, lung, AML, ovarian cancer or multiple myeloma.
  • Subjects must be able to complete on-line surveys using a cell phone, tablet, or computer.
  • All participants must be able to understand English.

Exclusion criteria

  • Any patient who cannot understand written or spoken English.
  • Any patient without the ability to complete on-line surveys using a cell phone, tablet, or computer.
  • Any patient on a treatment clinical trial.
  • Any prisoner and/or other vulnerable persons as defined by NIH (45 CFR 46, Subpart B, C and D).

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Other

Study locations

United States · 7 centers
  • Yale Cancer Center — New Haven
  • Northshore University Health System — Evanston
  • Univeristy of North Carolina at Chapel Hill — Chapel Hill
  • Duke — Durham
  • Cleveland Clinic Mercy Hospital — Canton
  • University Hospitals Seidman Cancer Center — Cleveland
  • Tri-County Hematology & Oncology Associates, Inc. — Massillon

Identifiers

NCT: NCT05974150 · OPT-IN Carevive Registry

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗